BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 30137283)

  • 1. Trends in High-grade Cervical Lesions and Cervical Cancer Screening in 5 States, 2008-2015.
    Gargano JW; Park IU; Griffin MR; Niccolai LM; Powell M; Bennett NM; Johnson Jones ML; Whitney E; Pemmaraju M; Brackney M; Abdullah N; Scahill M; Dahl RM; Cleveland AA; Unger ER; Markowitz LE;
    Clin Infect Dis; 2019 Apr; 68(8):1282-1291. PubMed ID: 30137283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Declines in Human Papillomavirus (HPV)-Associated High-Grade Cervical Lesions After Introduction of HPV Vaccines in Connecticut, United States, 2008-2015.
    Niccolai LM; Meek JI; Brackney M; Hadler JL; Sosa LE; Weinberger DM
    Clin Infect Dis; 2017 Sep; 65(6):884-889. PubMed ID: 28520854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population-based trends in high-grade cervical lesions in the early human papillomavirus vaccine era in the United States.
    Hariri S; Johnson ML; Bennett NM; Bauer HM; Park IU; Schafer S; Niccolai LM; Unger ER; Markowitz LE;
    Cancer; 2015 Aug; 121(16):2775-81. PubMed ID: 26098295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends in Human Papillomavirus Vaccine Types 16 and 18 in Cervical Precancers, 2008-2014.
    McClung NM; Gargano JW; Bennett NM; Niccolai LM; Abdullah N; Griffin MR; Park IU; Cleveland AA; Querec TD; Unger ER; Markowitz LE;
    Cancer Epidemiol Biomarkers Prev; 2019 Mar; 28(3):602-609. PubMed ID: 30792242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States - 2008-2012.
    Hariri S; Bennett NM; Niccolai LM; Schafer S; Park IU; Bloch KC; Unger ER; Whitney E; Julian P; Scahill MW; Abdullah N; Levine D; Johnson ML; Steinau M; Markowitz LE;
    Vaccine; 2015 Mar; 33(13):1608-13. PubMed ID: 25681664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimated Number of Cases of High-Grade Cervical Lesions Diagnosed Among Women - United States, 2008 and 2016.
    McClung NM; Gargano JW; Park IU; Whitney E; Abdullah N; Ehlers S; Bennett NM; Scahill M; Niccolai LM; Brackney M; Griffin MR; Pemmaraju M; Querec TD; Cleveland AA; Unger ER; Markowitz LE;
    MMWR Morb Mortal Wkly Rep; 2019 Apr; 68(15):337-343. PubMed ID: 30998672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction in cervical intraepithelial neoplasia in young women in British Columbia after introduction of the HPV vaccine: An ecological analysis.
    Ogilvie GS; Naus M; Money DM; Dobson SR; Miller D; Krajden M; van Niekerk DJ; Coldman AJ
    Int J Cancer; 2015 Oct; 137(8):1931-7. PubMed ID: 25754686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HPV type-specific trends in cervical precancers in the United States, 2008 to 2016.
    Gargano JW; McClung N; Lewis RM; Park IU; Whitney E; Castilho JL; Pemmaraju M; Niccolai LM; Brackney M; DeBess E; Ehlers S; Bennett NM; Scahill M; Cleveland AA; Querec TD; Unger ER; Markowitz LE;
    Int J Cancer; 2023 Jan; 152(2):137-150. PubMed ID: 35904861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in High-Grade Cervical Cancer Precursors in the Human Papillomavirus Vaccine Era.
    Oakley F; Desouki MM; Pemmaraju M; Gargano JM; Markowitz LE; Steinau M; Unger ER; Zhu Y; Fadare O; Griffin MR
    Am J Prev Med; 2018 Jul; 55(1):19-25. PubMed ID: 29778314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
    Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
    Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.
    Canfell K; Caruana M; Gebski V; Darlington-Brown J; Heley S; Brotherton J; Gertig D; Jennett CJ; Farnsworth A; Tan J; Wrede CD; Castle PE; Saville M
    PLoS Med; 2017 Sep; 14(9):e1002388. PubMed ID: 28926579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of 1, 2, and 3 Doses of Human Papillomavirus Vaccine Against High-Grade Cervical Lesions Positive for Human Papillomavirus 16 or 18.
    Johnson Jones ML; Gargano JW; Powell M; Park IU; Niccolai LM; Bennett NM; Griffin MR; Querec T; Unger ER; Markowitz LE;
    Am J Epidemiol; 2020 Apr; 189(4):265-276. PubMed ID: 31680146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human Papillomavirus Vaccine Impact on Cervical Precancers in a Low-Vaccination Population.
    Shing JZ; Griffin MR; Chang RS; Beeghly-Fadiel A; Sudenga SL; Slaughter JC; Pemmaraju M; Mitchel EF; Hull PC
    Am J Prev Med; 2022 Mar; 62(3):395-403. PubMed ID: 34756753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Declining rates of cervical intraepithelial neoplasia in British Columbia, Canada: An ecological analysis on the effects of the school-based human papillomavirus vaccination program.
    Donken R; van Niekerk D; Hamm J; Spinelli JJ; Smith L; Sadarangani M; Albert A; Money D; Dobson S; Miller D; Lee M; Mitchell-Foster S; Krajden M; Naus M; Ogilvie G
    Int J Cancer; 2021 Jul; 149(1):191-199. PubMed ID: 33586169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of human papillomavirus (HPV)-vaccine types by race/ethnicity and sociodemographic factors in women with high-grade cervical intraepithelial neoplasia (CIN2/3/AIS), Alameda County, California, United States.
    Saadeh K; Park I; Gargano JW; Whitney E; Querec TD; Hurley L; Silverberg M
    Vaccine; 2020 Jan; 38(1):39-45. PubMed ID: 31611099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cervical adenocarcinoma in situ: Human papillomavirus types and incidence trends in five states, 2008-2015.
    Cleveland AA; Gargano JW; Park IU; Griffin MR; Niccolai LM; Powell M; Bennett NM; Saadeh K; Pemmaraju M; Higgins K; Ehlers S; Scahill M; Johnson Jones ML; Querec T; Markowitz LE; Unger ER;
    Int J Cancer; 2020 Feb; 146(3):810-818. PubMed ID: 30980692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of human papillomavirus vaccination on the clinical meaning of cervical screening results.
    Castle PE; Xie X; Xue X; Poitras NE; Lorey TS; Kinney WK; Wentzensen N; Strickler HD; Burger EA; Schiffman M
    Prev Med; 2019 Jan; 118():44-50. PubMed ID: 30316878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent increase in incidence of cervical precancerous lesions in Norway: Nationwide study from 1992 to 2016.
    Orumaa M; Leinonen MK; Campbell S; Møller B; Myklebust TÅ; Nygård M
    Int J Cancer; 2019 Nov; 145(10):2629-2638. PubMed ID: 30734284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased Risk of High-grade Cervical Neoplasia in Women with Inflammatory Bowel Disease: A Case-controlled Cohort Study.
    Goetgebuer RL; Kreijne JE; Aitken CA; Dijkstra G; Hoentjen F; de Boer NK; Oldenburg B; van der Meulen AE; Ponsioen CIJ; Pierik MJ; van Kemenade FJ; de Kok IMCM; Siebers AG; Manniën J; van der Woude CJ; de Vries AC
    J Crohns Colitis; 2021 Sep; 15(9):1464-1473. PubMed ID: 33609353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.